Saga Investments LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Saga Investments LLC
Approval for the first-to-market COVID-19 vaccine would transform BioNTech – but major challenges in meeting global demand and for its oncology pipeline await.
An alert from the agency warns that the tests, which have become widely used for their speed and portability, carry a risk of false positives.
Germany is adjusting the national COVID-19 testing strategy, which from mid-October will include the use of antigen tests.
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
- Other Names / Subsidiaries
- deCODE genetics ehf